SSSW(SH:688399) Zheng Quan Ri Bao·2025-04-30 00:18Core Viewpoint - The company reported a steady recovery in its business operations during the first quarter of 2025, with a year-on-year revenue growth of 0.54% and a quarter-on-quarter growth of 12.37% despite external pressures [3]. Financial Performance - The company achieved operating revenue of 0.92 billion yuan in the first quarter of 2025, reflecting a year-on-year increase of 0.54% and a quarter-on-quarter increase of 12.37% [3]. - The overseas market showed significant growth, with overseas revenue increasing by 69.00% year-on-year due to prior product certifications and strategic deployment [3]. - The net profit declined due to price pressures from centralized procurement in the in vitro diagnostics industry, a VAT adjustment on self-produced testing reagents to 13%, and a reduction in government subsidies [3]. Asset Impairment - The company conducted impairment testing on its assets as of March 31, 2025, and recognized a total impairment provision of 59.06 thousand yuan, which included 18.64 thousand yuan for expected credit losses and 40.42 thousand yuan for inventory write-downs [13][14]. - The impairment provisions are expected to increase the company's profit before tax by 318.29 thousand yuan for the first quarter of 2025 [14]. Governance and Compliance - The board of directors and the supervisory board confirmed the accuracy and completeness of the quarterly report, ensuring compliance with relevant laws and regulations [2][8]. - The supervisory board reviewed and approved the first quarter report, affirming that it reflects the company's financial status and operational results accurately [8][9].